DT678
Anti-platelet therapy (e.g., stroke, MI prevention)
Pre-clinicalActive
Key Facts
Indication
Anti-platelet therapy (e.g., stroke, MI prevention)
Phase
Pre-clinical
Status
Active
Company
About Diapin Therapeutics
Diapin Therapeutics is a private, clinical-stage biotech leveraging licensed and internally developed technologies to address significant unmet needs in cardiovascular and metabolic diseases. Its lead assets are DT109, a compound showing promise in MASH and atherosclerosis, and DT678, an orally available prodrug designed to overcome limitations of the blockbuster antiplatelet drug clopidogrel. The company is strategically positioned with commercial rights retained for most global territories and has established key academic and industry collaborations to advance its programs.
View full company profile